At the 2025 NAPNAP Conference in Chicago, Jessica Spruit, DNP, CPNP-AC, FAANP, discussed the AAP's first clinical practice guideline on opioid prescribing. At the 2025 NAPNAP National Conference on ...

Bobbie Monaco, MSN, CPNP-PC, provided a recap of her NAPNAP session regarding period poverty, and called for continued advocacy and awareness in the United States and globally. At the 2025 NAPNAP ...

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, highlighted key updates on influenza, COVID-19, and RSV vaccines at the 2025 NAPNAP National Conference. At the 2025 NAPNAP National Conference on ...

Social media data mining may improve STI testing rates and sexual health outreach among young Black males, according to a study presented at the 2025 NAPNAP conference. According to the study authors, ...

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, comments on the ongoing measles outbreaks and encourages advocation for vaccines and accurate information. Measles cases have continued to ...

Early anxiety screening in pediatric primary care improves detection, outcomes, and access to mental health support starting at age 8. A new narrative review presented at the 2025 NAPNAP National ...

In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact. Emerging research in food allergy and anaphylaxis is ...

In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management. Advances in pediatric food allergy and anaphylaxis ...

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education. In this Contemporary Pediatrics and HCPLive RX Review discussion, ...

In part 1 of this 5-part series, panelists discuss early allergen introduction, oral immunotherapy, and Xolair for food allergy. The role of needle-free epinephrine in pediatric allergy for 2025 ...

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management. Traister notes that while intranasal epinephrine offers a ...

If approved, SYD-101 would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. Sydnexis has announced that the FDA has accepted its ...